Clinical trials in isolated systolic hypertension

被引：4

作者：

Gasowski J. ^{[1
,2
]}

Wang J.G. ^{[1
,3
]}

Staessen J.A. ^{[1
]}

机构：

[1] Studiecoördinatiecentrum, Laboratorium Hypertensie, Campus Gasthuisberg, Herestraat 49

[2] Jagiellonian University, School of Medicine, Department of Gerontology and Family Medicine, Cracow

[3] Fuwai Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing

来源：

Current Hypertension Reports | 1999年 / 1卷 / 5期

关键词：

Systolic Hypertension; Nonfatal Stroke; Isolate Systolic Hypertension; European Working Party; Systolic Hyper;

D O I：

10.1007/s11906-999-0053-2

中图分类号：

学科分类号：

摘要：

Isolated systolic hypertension affects 8% to 15% of all people older than 60 years of age. In the elderly, systolic hypertension is the major modifiable cardiovascular risk factor. Three placebo-controlled outcome trials on antihypertensive drug treatment of this disorder have been published. This article briefly reviews the main findings of each of these three trials and presents pooled estimates of the benefit of antihypertensive drug treatment for elderly patients with isolated systolic hypertension. A total of 11,825 patients were enrolled in the Systolic Hypertension in the Elderly Program (SHEP, n = 4736), the Systolic Hypertension in Europe (Syst-Eur, n = 4695), and the Systolic Hypertension in China (Syst-China, n = 2394) trials. The outcome results of these trials were pooled by calculating the common odds ratio for active versus placebo treatment. The pooled results of the outcome trials in older patients with isolated systolic hypertension prove that antihypertensive drug treatment must be prescribed if, on repeated measurement, systolic blood pressure is 160 mm Hg or higher. Copyright © 1999 by Current Science Inc.

引用

页码：387 / 393

页数：6

共 42 条

[1]

Kannel, W.B., Gordon, T., Evaluation of cardiovacular risk in the elderly: The Framingham study (1978) Bull N Y Acad Med, 54, pp. 573-591

[2]

Staessen, J., O'Brien, E., Atkins, N., The increase in blood pressure with age and body mass index is overestimated by conventional sphygmomanometry (1992) Am J Epidemiol, 136, pp. 450-459

[3]

Staessen, J., Amery, A., Fagard, R., Isolated systolic hypertension in the elderly [editorial] (1990) J Hypertens, 8, pp. 393-405

[4]

Buck, C., Baker, P., Bass, M., Donner, A., The prognosis of hypertension according to age at onset (1987) Hypertension, 9, pp. 204-208

[5]

Thijs, L., Fagard, R., Lijnen, P., Why is antihypertensive drug therapy needed in elderly patients with systolodiastolic hypertension? (1994) J Hypertens, 12 (SUPPL.), pp. 25-34

[6]

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP) (1991) JAMA, 265, pp. 3255-3264. , SHEP Cooperative Research Group

[7]

Staessen, J.A., Fagard, R., Thijs, L., Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension (1997) Lancet, 350, pp. 757-764

[8]

Liu, L., Wang, J.G., Gong, L., Comparison of active treatment and placebo for older patients with isolated systolic hypertension (1998) J Hypertens, 16, pp. 1823-1829

[9]

Implications of the systolic hypertension in the elderly program (1993) Hypertension, 21, pp. 335-343. , The Systolic Hypertension in the Elderly Program Cooperative Research Group

[10]

Curb, J.D., Pressel, S.L., Cutler, J.A., Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension (1996) JAMA, 276, pp. 1886-1892. , Systolic Hypertension in the Elderly Cooperative Research Group

← 1 2 3 4 5 →